Skip to main content
Evidence Snapshot

Retinoic acid receptor beta

CHEMBL2008 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2008
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Retinoic acid receptor beta as ChEMBL target CHEMBL2008, mapped to UniProt P10826. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Retinoic acid receptor beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2008
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10826
Retinoic acid receptor beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Retinoic acid receptor beta matters

As of 2026-09-13

Retinoic acid receptor beta is reviewed as Retinoic acid receptor beta (UniProt P10826); Retinoic acid receptor beta shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 17 approved drugs, 715 compounds, and 254 assays, with lead potency reaching pChEMBL 9.5.

Disease context
myelodysplastic syndrome

Retinoic acid receptor beta shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TAMIBAROTENE.

Start review with myelodysplastic syndrome because it currently carries late clinical support. Linked drugs include TAMIBAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 715 compounds, and 254 assays for this target. The dominant activity type is EC50. CHEMBL451835 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL451835 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Retinoic acid receptor beta matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10826, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why myelodysplastic syndrome is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

715
Total Compounds
254
Total Assays
17
Approved Drugs
IC50: 70.0, KI: 123.0, EC50: 354.0, KD: 143.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL451835
 9.5 EC50 —
No preferred name
CHEMBL5997757
 9.5 EC50 —
No preferred name
CHEMBL12585
 9.4 EC50 —
No preferred name
CHEMBL441231
 9.4 EC50 —
No preferred name
CHEMBL38
 9.4 Ki Approved

Approved Drugs

Structure Compound First Approval
TRIFAROTENE
CHEMBL3707313
 2019
TAMIBAROTENE
CHEMBL25202
 2005
ALITRETINOIN
CHEMBL705
 1999
BEXAROTENE
CHEMBL1023
 1999
TAZAROTENE
CHEMBL1657
 1997
ADAPALENE
CHEMBL1265
 1996
TRETINOIN
CHEMBL38
 1971
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2008